Reig Jofre begins a clinical study to reduce the incidence of COVID-19 and its severity in the event of infection
- Reig Jofre is the force behind a clinical study to evaluate the efficacy of the Manremyc® food supplement for those health professionals who are most exposed to the risk of contracting COVID19
- Reig Jofre expects to obtain the results in October 2020. In the event of Manremyc® proving effective against COVID19, it could be supplied for general use very easily
- The study will be carried out in coordination with the Germans Trias i Pujol Research Institute (IGTP) together with the Institute for Research in Primary Care Jordi Gol
Reig Jofre, a pharmaceutical company listed on the Spanish continuous market, is to begin a double-blind clinical study among a group of 300 health professionals with a high risk of contracting COVID-19. The participants will be administered Manremyc®, an oral food supplement based on heatinactivated Mycobacterium s. manresensis bacilli, in order to assess its efficacy in reducing the incidence of SARS-CoV-2 infection and, in the event of infection, to demonstrate its capacity to reduce the severity of the infection.
Manremyc® is the result of the research and development work carried out over more than 10 years by the Experimental Tuberculosis Unit of the Germans Trias i Pujol Research Institute (IGTP). Countries in which mass vaccination is employed against TB have been found to have a lower incidence of COVID-19, due to the corresponding stimulation of innate immunity. This property is also induced by Manremyc®, in addition to an anti-inflammatory response in the lungs. The progression of a Mycobacterium tuberculosis infection to tuberculosis (TB) is due to an excessive inflammatory response. The administration of Manremyc® generates a balanced immune response which enables such inflammation in lung lesions to be avoided.